Sutro Biopharma (STRO) Free Cash Flow (2017 - 2025)

Sutro Biopharma has disclosed Free Cash Flow across 9 years of filings, most recently posting -$26.4 million for Q4 2025.

• Free Cash Flow for Q4 2025 came in at -$26.4 million, up 62.52% year-over-year; the trailing twelve-month figure through Dec 2025 was -$177.2 million (up 7.79% YoY), and the FY2025 annual result was -$177.2 million, up 7.79% from the prior year.
• Free Cash Flow came in at -$26.4 million for Q4 2025 at Sutro Biopharma, up from -$38.2 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $67.8 million in Q3 2022 to a low of -$70.4 million in Q4 2024.
• The 5-year median for Free Cash Flow is -$34.3 million (2021), against an average of -$28.4 million.
• Across the five-year window, Free Cash Flow soared 289.39% in 2022 and slumped 545.62% in 2025, its largest moves.
• Sutro Biopharma's Free Cash Flow stood at -$9.2 million in 2021, then plunged by 226.79% to -$29.9 million in 2022, then jumped by 155.87% to $16.7 million in 2023, then tumbled by 520.64% to -$70.4 million in 2024, then soared by 62.52% to -$26.4 million in 2025.
• The last three Free Cash Flow figures came in at -$26.4 million (Q4 2025), -$38.2 million (Q3 2025), and -$43.6 million (Q2 2025), per Business Quant data.